Revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.
The company’s Board has also declared a dividend of Rs 8 per share on the face value of Rs 2 each for the financial year ended March 2024.
EBITDA for the reporting quarter rose by a robust 67% YoY to Rs 1,026 crore. It was Rs 615 crore a year ago. EBITDA margins, meanwhile, expanded 680 basis points compared with the year-ago period to 21%.
“We continue to move forward with sustainable and profitable growth and delivered another strong set of numbers in Q4,” said Nilesh Gupta, MD, Lupin.US sales remained healthy during the quarter, driven by inhalation products, and the India formulation business is delivering ahead of the market.”While FY24 has been a year of resurgence for the company, we look forward to an even stronger FY25 driven by growth across our key geographies and consistent improvement in our margins,” Gupta further said.Region wise, North America sales were Rs 1901 crore, up 22% YoY and accounted for 39% of Lupin’s global sales. The US during the quarter was at $209 million, down from $212 million in the preceding quarter, but higher than $175 million in the previous year quarter.
The company filed 1 ANDA in the quarter, received 12 ANDA approvals from the US FDA, and launched 6 products in the quarter in the US Lupin now has 161 generic products in the US.
The company continues to be the third largest pharmaceutical player in both the US generic market and US total market by prescriptions.
Meanwhile, India formulation sales were up 8% YoY to Rs 1601 crore, accounting for 33% of Lupin’s global sales. Growth markets sales for the fourth quarter increased 16% YoY to Rs 509 crore.
The global API sales for the reporting quarter were down 20% YoY to Rs 258 crore.
